<p>橡树收获投资服务在第三季度收购了 Teva Pharmaceutical Industries Ltd.（纽约证券交易所代码：TEVA - 免费报告）的新股份，根据其最近向美国证券交易委员会（SEC）披露的信息。该公司收购了 50,000 股该公司的股票，价值约为 1,010,000 美元。</p>
<ul>
<li>MarketBeat 周报 – 02/03 - 02/07</li>
</ul>
<p>其他几家对冲基金最近也调整了对该股票的持有。Lansforsakringar Fondforvaltning AB publ 在第一季度将其在 Teva Pharmaceutical Industries 的股份增加了 2.2%。Lansforsakringar Fondforvaltning AB publ 目前拥有 250,106 股该公司的股票，价值 3,844,000 美元，此前在上个季度又收购了 5,344 股。Trexquant Investment LP 在第一季度将其在 Teva Pharmaceutical Industries 的股份增加了 114.8%。Trexquant Investment LP 目前拥有 203,909 股该公司的股票，价值 3,134,000 美元，此前在上个季度又购买了 108,986 股。加拿大养老金计划投资委员会在第一季度将其在 Teva Pharmaceutical Industries 的股份增加了 109.2%。加拿大养老金计划投资委员会目前拥有 150,638 股该公司的股票，价值 2,315,000 美元，此前在上个季度又购买了 78,638 股。新英格兰退休规划公司在第一季度将其在 Teva Pharmaceutical Industries 的持股增加了 97.2%。新英格兰退休规划公司目前拥有 31,228 股该公司的股票，价值 480,000 美元，此前在上个季度又购买了 15,393 股。最后，加拿大皇家银行在第一季度将其在 Teva Pharmaceutical Industries 的股份增加了 0.4%。加拿大皇家银行目前拥有 1,181,964 股该公司的股票，价值 18,167,000 美元，此前在上个季度又购买了 4,361 股。对冲基金和其他机构投资者持有该公司 54.05% 的股票。</p>
<h2>Teva Pharmaceutical Industries 股价表现</h2>
<p>Teva Pharmaceutical Industries 的股票在周二开盘价为 31.58 美元。该公司的市值为 362.2 亿美元，市盈率为 52.63，市盈增长比率为 1.90，贝塔值为 0.66。Teva Pharmaceutical Industries Ltd.的 12 个月最低价为 12.47 美元，12 个月最高价为 31.99 美元。该公司的 50 日移动平均价格为 25.87 美元，200 日移动平均价格为 20.67 美元。该公司的流动比率为 1.11，速动比率为 0.82，债务股本比率为 2.31。</p>
<h2>分析师评级调整</h2>
<ul>
<li>Teva Pharma：为什么这家仿制药巨头现在是一个明智的投资</li>
</ul>
<p>多位分析师对 TEVA 股票发布了报告。美国银行在 2022 年 12 月 9 日的研究报告中将 Teva Pharmaceutical Industries 的目标价从 29.00 美元上调至 32.00 美元，并给予该股票 “买入” 评级。Piper Sandler 在 2022 年 12 月 22 日的研究报告中将 Teva Pharmaceutical Industries 的目标价从 30.00 美元上调至 40.00 美元，并给予该公司 “增持” 评级。瑞银集团在 2022 年 9 月 24 日的研究报告中将 Teva Pharmaceutical Industries 的目标价从 23.00 美元上调至 26.00 美元，并给予该股票 “买入” 评级。华尔街 Zen 在 2022 年 12 月 13 日的报告中将 Teva Pharmaceutical Industries 的评级从 “强烈买入” 下调至 “买入”。最后，Weiss Ratings 在 2022 年 10 月 8 日的研究报告中重申了对 Teva Pharmaceutical Industries 的 “卖出（d-）” 评级。三位投资分析师对该股票给予了 “强烈买入” 评级，六位给予了 “买入” 评级，一位给予了 “卖出” 评级。根据 MarketBeat.com 的数据，该股票目前的共识评级为 “买入”，平均目标价为 32.88 美元。</p>
<p><strong>查看我们最新的 TEVA 股票报告</strong></p>
<h2>内部交易活动</h2>
<ul>
<li>2 只仿制药股票准备在 2025 年大幅上涨</li>
</ul>
<p>在相关消息中，副总裁 Richard Daniell 在 2022 年 12 月 9 日以每股平均价格 28.68 美元出售了 115,468 股公司的股票，总交易额为 3,311,622.24 美元。交易完成后，副总裁在公司中持有 48,384 股，价值 1,387,653.12 美元。此次交易使其持股减少了 70.47%。该交易已在美国证券交易委员会的法律文件中披露，相关信息可通过此链接获取。此外，首席会计官 Amir Weiss 在 2022 年 12 月 16 日以每股平均价格 30.20 美元出售了 12,300 股公司的股票，总价值为 371,460.00 美元。交易完成后，首席会计官直接持有 5,650 股公司股票，价值 170,630 美元。此次交易使其持股减少了 68.52%。有关此次出售的更多细节可在官方 SEC 披露中找到。在过去的九十天里，内部人士出售了价值 17,076,965 美元的 622,060 股公司股票。目前公司内部人士持有 0.55% 的股票。</p>
<h2>Teva Pharmaceutical Industries 公司简介</h2>
<p>（免费报告）</p>
<p>Teva Pharmaceutical Industries Ltd. NYSE: TEVA 是一家以色列跨国制药公司，也是全球最大的仿制药制造商之一。该公司的核心业务包括仿制药的开发、生产和营销，以及一系列专利品牌药物的组合。Teva 向全球市场提供成品剂型和活性药物成分（API），并在多个国家运营制造和研究设施。</p>
<p>Teva 的产品范围涵盖口服固体剂型、注射剂、吸入产品和其他剂型，涉及中枢神经系统疾病、呼吸系统、肿瘤、疼痛和传染病等治疗领域。</p>
<h2>精选文章</h2>
<ul>
<li>我们更看好的五只股票，胜过戴珊制药</li>
<li>华尔街选股者评选 2026 年第一股票</li>
<li>请勿删除，立即阅读</li>
<li>家族信托如何帮助保护您的财富</li>
<li>您的 “继承权” 刚刚被激活</li>
<li>将您的 “死钱” 转变为每月 306 美元以上（从这个月开始）</li>
</ul>
<p><strong>想看看其他对 TEVA 感兴趣的对冲基金持有哪些股票吗？</strong> 请访问 HoldingsChannel.com 获取戴珊制药有限公司（NYSE:TEVA - 免费报告）的最新 13F 文件和内部交易信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVRFVkE?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVRFVkE"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com.</em></p>
<h2>您现在应该投资 1,000 美元在戴珊制药吗？</h2>
<p>在您考虑戴珊制药之前，您需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而戴珊制药并不在名单上。</p>
<p>虽然戴珊制药目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

梯瓦制药

<p>橡树收获投资服务公司已收购 50,000 股梯瓦制药（Teva Pharmaceutical Industries Ltd.，纽约证券交易所代码：TEVA），价值约为 1,010,000 美元。此次收购发生在第三季度，已向美国证券交易委员会（SEC）披露。其他对冲基金也增加了在梯瓦的持股，其中兰斯福萨金基金管理公司（Lansforsakringar Fondforvaltning AB）、Trexquant Investment LP 和加拿大养老计划投资委员会（Canada Pension Plan Investment Board）的增持尤为显著。梯瓦的股票目前交易价格为 31.58 美元，市值为 362.2 亿美元，分析师一致给予 “买入” 的评级</p>

<p>Oak Harvest Investment Services acquired a new stake in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Free Report) in the third quarter, according to its most recent disclosure with the SEC. The firm acquired 50,000 shares of the company's stock, valued at approximately $1,010,000.</p>
<div class="lb-trans"><p>橡树收获投资服务在第三季度收购了 Teva Pharmaceutical Industries Ltd.（纽约证券交易所代码：TEVA - 免费报告）的新股份，根据其最近向美国证券交易委员会（SEC）披露的信息。该公司收购了 50,000 股该公司的股票，价值约为 1,010,000 美元。</p>
</div><ul>
<li>MarketBeat Week in Review – 02/03 - 02/07</li>
</ul>
<div class="lb-trans"><ul>
<li>MarketBeat 周报 – 02/03 - 02/07</li>
</ul>
</div><p>Several other hedge funds have also recently modified their holdings of the stock. Lansforsakringar Fondforvaltning AB publ grew its stake in Teva Pharmaceutical Industries by 2.2% during the first quarter. Lansforsakringar Fondforvaltning AB publ now owns 250,106 shares of the company's stock valued at $3,844,000 after acquiring an additional 5,344 shares in the last quarter. Trexquant Investment LP grew its position in shares of Teva Pharmaceutical Industries by 114.8% during the first quarter. Trexquant Investment LP now owns 203,909 shares of the company's stock valued at $3,134,000 after purchasing an additional 108,986 shares in the last quarter. Canada Pension Plan Investment Board grew its position in shares of Teva Pharmaceutical Industries by 109.2% during the first quarter. Canada Pension Plan Investment Board now owns 150,638 shares of the company's stock valued at $2,315,000 after purchasing an additional 78,638 shares in the last quarter. Retirement Planning Co of New England Inc. increased its holdings in shares of Teva Pharmaceutical Industries by 97.2% in the first quarter. Retirement Planning Co of New England Inc. now owns 31,228 shares of the company's stock worth $480,000 after purchasing an additional 15,393 shares during the last quarter. Finally, Royal Bank of Canada lifted its position in shares of Teva Pharmaceutical Industries by 0.4% in the first quarter. Royal Bank of Canada now owns 1,181,964 shares of the company's stock worth $18,167,000 after buying an additional 4,361 shares in the last quarter. Hedge funds and other institutional investors own 54.05% of the company's stock.</p>
<div class="lb-trans"><p>其他几家对冲基金最近也调整了对该股票的持有。Lansforsakringar Fondforvaltning AB publ 在第一季度将其在 Teva Pharmaceutical Industries 的股份增加了 2.2%。Lansforsakringar Fondforvaltning AB publ 目前拥有 250,106 股该公司的股票，价值 3,844,000 美元，此前在上个季度又收购了 5,344 股。Trexquant Investment LP 在第一季度将其在 Teva Pharmaceutical Industries 的股份增加了 114.8%。Trexquant Investment LP 目前拥有 203,909 股该公司的股票，价值 3,134,000 美元，此前在上个季度又购买了 108,986 股。加拿大养老金计划投资委员会在第一季度将其在 Teva Pharmaceutical Industries 的股份增加了 109.2%。加拿大养老金计划投资委员会目前拥有 150,638 股该公司的股票，价值 2,315,000 美元，此前在上个季度又购买了 78,638 股。新英格兰退休规划公司在第一季度将其在 Teva Pharmaceutical Industries 的持股增加了 97.2%。新英格兰退休规划公司目前拥有 31,228 股该公司的股票，价值 480,000 美元，此前在上个季度又购买了 15,393 股。最后，加拿大皇家银行在第一季度将其在 Teva Pharmaceutical Industries 的股份增加了 0.4%。加拿大皇家银行目前拥有 1,181,964 股该公司的股票，价值 18,167,000 美元，此前在上个季度又购买了 4,361 股。对冲基金和其他机构投资者持有该公司 54.05% 的股票。</p>
</div><h2>Teva Pharmaceutical Industries Price Performance</h2>
<div class="lb-trans"><h2>Teva Pharmaceutical Industries 股价表现</h2>
</div><p>Teva Pharmaceutical Industries stock opened at $31.58 on Tuesday. The firm has a market capitalization of $36.22 billion, a PE ratio of 52.63, a price-to-earnings-growth ratio of 1.90 and a beta of 0.66. Teva Pharmaceutical Industries Ltd. has a 12-month low of $12.47 and a 12-month high of $31.99. The firm has a 50-day moving average price of $25.87 and a 200-day moving average price of $20.67. The company has a current ratio of 1.11, a quick ratio of 0.82 and a debt-to-equity ratio of 2.31.</p>
<div class="lb-trans"><p>Teva Pharmaceutical Industries 的股票在周二开盘价为 31.58 美元。该公司的市值为 362.2 亿美元，市盈率为 52.63，市盈增长比率为 1.90，贝塔值为 0.66。Teva Pharmaceutical Industries Ltd.的 12 个月最低价为 12.47 美元，12 个月最高价为 31.99 美元。该公司的 50 日移动平均价格为 25.87 美元，200 日移动平均价格为 20.67 美元。该公司的流动比率为 1.11，速动比率为 0.82，债务股本比率为 2.31。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析师评级调整</h2>
</div><ul>
<li>Teva Pharma: Why This Generic Drug Giant Is a Smart Buy Now</li>
</ul>
<div class="lb-trans"><ul>
<li>Teva Pharma：为什么这家仿制药巨头现在是一个明智的投资</li>
</ul>
</div><p>A number of analysts have issued reports on TEVA shares. Bank of America lifted their price objective on Teva Pharmaceutical Industries from $29.00 to $32.00 and gave the stock a &#34;buy&#34; rating in a research note on Tuesday, December 9th. Piper Sandler upped their price target on shares of Teva Pharmaceutical Industries from $30.00 to $40.00 and gave the company an &#34;overweight&#34; rating in a research note on Monday, December 22nd. UBS Group lifted their price objective on shares of Teva Pharmaceutical Industries from $23.00 to $26.00 and gave the stock a &#34;buy&#34; rating in a research note on Wednesday, September 24th. Wall Street Zen downgraded shares of Teva Pharmaceutical Industries from a &#34;strong-buy&#34; rating to a &#34;buy&#34; rating in a report on Saturday, December 13th. Finally, Weiss Ratings reiterated a &#34;sell (d-)&#34; rating on shares of Teva Pharmaceutical Industries in a research report on Wednesday, October 8th. Three investment analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of &#34;Buy&#34; and an average target price of $32.88.</p>
<div class="lb-trans"><p>多位分析师对 TEVA 股票发布了报告。美国银行在 2022 年 12 月 9 日的研究报告中将 Teva Pharmaceutical Industries 的目标价从 29.00 美元上调至 32.00 美元，并给予该股票 “买入” 评级。Piper Sandler 在 2022 年 12 月 22 日的研究报告中将 Teva Pharmaceutical Industries 的目标价从 30.00 美元上调至 40.00 美元，并给予该公司 “增持” 评级。瑞银集团在 2022 年 9 月 24 日的研究报告中将 Teva Pharmaceutical Industries 的目标价从 23.00 美元上调至 26.00 美元，并给予该股票 “买入” 评级。华尔街 Zen 在 2022 年 12 月 13 日的报告中将 Teva Pharmaceutical Industries 的评级从 “强烈买入” 下调至 “买入”。最后，Weiss Ratings 在 2022 年 10 月 8 日的研究报告中重申了对 Teva Pharmaceutical Industries 的 “卖出（d-）” 评级。三位投资分析师对该股票给予了 “强烈买入” 评级，六位给予了 “买入” 评级，一位给予了 “卖出” 评级。根据 MarketBeat.com 的数据，该股票目前的共识评级为 “买入”，平均目标价为 32.88 美元。</p>
</div><p><strong>View Our Latest Stock Report on TEVA</strong></p>
<div class="lb-trans"><p><strong>查看我们最新的 TEVA 股票报告</strong></p>
</div><h2>Insider Activity</h2>
<div class="lb-trans"><h2>内部交易活动</h2>
</div><ul>
<li>2 Generic Drug Stocks Ready to Surge in 2025</li>
</ul>
<div class="lb-trans"><ul>
<li>2 只仿制药股票准备在 2025 年大幅上涨</li>
</ul>
</div><p>In related news, VP Richard Daniell sold 115,468 shares of the business's stock in a transaction on Tuesday, December 9th. The stock was sold at an average price of $28.68, for a total transaction of $3,311,622.24. Following the completion of the transaction, the vice president owned 48,384 shares in the company, valued at $1,387,653.12. The trade was a 70.47% decrease in their position. The transaction was disclosed in a legal filing with the Securities &amp; Exchange Commission, which is available through this hyperlink. Also, CAO Amir Weiss sold 12,300 shares of the company's stock in a transaction on Tuesday, December 16th. The shares were sold at an average price of $30.20, for a total value of $371,460.00. Following the completion of the transaction, the chief accounting officer directly owned 5,650 shares in the company, valued at $170,630. This trade represents a 68.52% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 622,060 shares of company stock worth $17,076,965 in the last ninety days. 0.55% of the stock is currently owned by company insiders.</p>
<div class="lb-trans"><p>在相关消息中，副总裁 Richard Daniell 在 2022 年 12 月 9 日以每股平均价格 28.68 美元出售了 115,468 股公司的股票，总交易额为 3,311,622.24 美元。交易完成后，副总裁在公司中持有 48,384 股，价值 1,387,653.12 美元。此次交易使其持股减少了 70.47%。该交易已在美国证券交易委员会的法律文件中披露，相关信息可通过此链接获取。此外，首席会计官 Amir Weiss 在 2022 年 12 月 16 日以每股平均价格 30.20 美元出售了 12,300 股公司的股票，总价值为 371,460.00 美元。交易完成后，首席会计官直接持有 5,650 股公司股票，价值 170,630 美元。此次交易使其持股减少了 68.52%。有关此次出售的更多细节可在官方 SEC 披露中找到。在过去的九十天里，内部人士出售了价值 17,076,965 美元的 622,060 股公司股票。目前公司内部人士持有 0.55% 的股票。</p>
</div><h2>Teva Pharmaceutical Industries Profile</h2>
<div class="lb-trans"><h2>Teva Pharmaceutical Industries 公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Teva Pharmaceutical Industries Ltd. NYSE: TEVA is an Israeli multinational pharmaceutical company and one of the world's largest manufacturers of generic medicines. The company's core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.</p>
<div class="lb-trans"><p>Teva Pharmaceutical Industries Ltd. NYSE: TEVA 是一家以色列跨国制药公司，也是全球最大的仿制药制造商之一。该公司的核心业务包括仿制药的开发、生产和营销，以及一系列专利品牌药物的组合。Teva 向全球市场提供成品剂型和活性药物成分（API），并在多个国家运营制造和研究设施。</p>
</div><p>Teva's product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.</p>
<div class="lb-trans"><p>Teva 的产品范围涵盖口服固体剂型、注射剂、吸入产品和其他剂型，涉及中枢神经系统疾病、呼吸系统、肿瘤、疼痛和传染病等治疗领域。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精选文章</h2>
</div><ul>
<li>Five stocks we like better than Teva Pharmaceutical Industries</li>
<li>Wall Street Stockpicker Names #1 Stock of 2026</li>
<li>Do not delete, read immediately</li>
<li>How a Family Trust May Be Able To Help Preserve Your Wealth</li>
<li>Your “birthright claim” just got activated</li>
<li>Turn your &#34;dead money&#34; into $306+ monthly (starting this month)</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，胜过戴珊制药</li>
<li>华尔街选股者评选 2026 年第一股票</li>
<li>请勿删除，立即阅读</li>
<li>家族信托如何帮助保护您的财富</li>
<li>您的 “继承权” 刚刚被激活</li>
<li>将您的 “死钱” 转变为每月 306 美元以上（从这个月开始）</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding TEVA?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他对 TEVA 感兴趣的对冲基金持有哪些股票吗？</strong> 请访问 HoldingsChannel.com 获取戴珊制药有限公司（NYSE:TEVA - 免费报告）的最新 13F 文件和内部交易信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVRFVkE" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=TEVA"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Teva Pharmaceutical Industries Right Now?</h2>
<div class="lb-trans"><h2>您现在应该投资 1,000 美元在戴珊制药吗？</h2>
</div><p>Before you consider Teva Pharmaceutical Industries, you'll want to hear this.</p>
<div class="lb-trans"><p>在您考虑戴珊制药之前，您需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Teva Pharmaceutical Industries wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而戴珊制药并不在名单上。</p>
</div><p>While Teva Pharmaceutical Industries currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然戴珊制药目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Oak Harvest 投资服务公司收购了梯瓦制药工业有限公司的 50,000 股股票